Literature DB >> 25531827

Estimation of background incidence rates of Guillain-Barré syndrome in Germany - a retrospective cohort study with electronic healthcare data.

Sabrina Hense1, Tania Schink, Stefan H Kreisel, Lydie Marcelon, François Simondon, Maike Tahden, Edeltraut Garbe.   

Abstract

BACKGROUND: The Guillain-Barré syndrome (GBS) occurs after infections and as an adverse reaction to vaccines. No detailed information on incidence rates (IRs) in Germany is available.
METHODS: This retrospective cohort study estimated age- and sex-specific IRs of GBS in Germany in the years 2007-2009 based on electronic healthcare data from the German Pharmacoepidemiological Research Database (GePaRD). Two case definitions were applied. GBS cases had a main discharge diagnosis of GBS. GBS_PROCEDURE cases in addition had codes for relevant diagnostic procedures. Crude and standardized IRs (SIRs) with 95% confidence intervals were stratified by year, age group, sex, region and season. IR ratios (IRRs) for each stratification factor were calculated by multivariable Poisson regression.
RESULTS: Among 13,297,678 persons, 889 (693) incident GBS (GBS_PROCEDURE) cases were identified. Overall SIRs per 100,000 person years were 2.4 (2.2-2.5) for GBS and 1.8 (1.7-2.0) for GBS_PROCEDURE. (S)IRs increased with age, peaking in the age group 70-79 years (IR GBS: 5.5 (4.7-6.5)) and were higher in males than in females (e.g., IR GBS: IRR = 1.5 (1.3-1.7)) and in February-April, as compared to the rest of the year. No regional pattern was observed.
CONCLUSION: (S)IRs of GBS in Germany differed by age, sex and season and were comparable to those found in other studies. RESULTS might be used as a comparator in vaccine safety monitoring.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 25531827     DOI: 10.1159/000369344

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  4 in total

1.  Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study.

Authors:  Xintong Li; Anna Ostropolets; Rupa Makadia; Azza Shoaibi; Gowtham Rao; Anthony G Sena; Eugenia Martinez-Hernandez; Antonella Delmestri; Katia Verhamme; Peter R Rijnbeek; Talita Duarte-Salles; Marc A Suchard; Patrick B Ryan; George Hripcsak; Daniel Prieto-Alhambra
Journal:  BMJ       Date:  2021-06-14

2.  Epidemiology of Guillain-Barré syndrome in Finland 2004-2014.

Authors:  Jussi O T Sipilä; Merja Soilu-Hänninen; Jori O Ruuskanen; Päivi Rautava; Ville Kytö
Journal:  J Peripher Nerv Syst       Date:  2017-11-15       Impact factor: 3.494

3.  Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series.

Authors:  Leon D Kaulen; Sofia Doubrovinskaia; Christoph Mooshage; Berit Jordan; Jan Purrucker; Carmen Haubner; Corinna Seliger; Hanns-Martin Lorenz; Simon Nagel; Brigitte Wildemann; Martin Bendszus; Wolfgang Wick; Silvia Schönenberger
Journal:  Eur J Neurol       Date:  2021-10-31       Impact factor: 6.288

4.  Factors Influencing Background Incidence Rate Calculation: Systematic Empirical Evaluation Across an International Network of Observational Databases.

Authors:  Anna Ostropolets; Xintong Li; Rupa Makadia; Gowtham Rao; Peter R Rijnbeek; Talita Duarte-Salles; Anthony G Sena; Azza Shaoibi; Marc A Suchard; Patrick B Ryan; Daniel Prieto-Alhambra; George Hripcsak
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.